Claims for Patent: 7,829,659

Summary for Patent: 7,829,659

Title:	Methods of modifying polypeptides comprising non-natural amino acids
Abstract:	The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
Inventor(s):	Grabstein; Kenneth H. (Mercer Island, WA), Wang; Aijun (Sammamish, WA), Nairn; Natalie Winblade (Seattle, WA), Graddis; Thomas James (Seattle, WA)
Assignee:	Allozyne, Inc. (Seattle, WA)
Application Number:	12/105,154
Patent Claims:	1. A method of modifying a polypeptide containing a non-natural amino acid, comprising incorporating a chemical moiety into said polypeptide by a chemical reaction selected from the group consisting of: palladium-catalyzed Suzuki coupling, palladium-catalyzed Sonogashira coupling, palladium-catalyzed Heck coupling, palladium-catalyzed Hiyama coupling and Huisgen copper-catalyzed [3+2] cycloaddition, in the presence of micelles, wherein said modified polypeptide retains its native function. 2. The method of claim 1, further comprising refolding the polypeptide after incorporating the chemical moiety into the polypeptide. 3. The method of claim 1, wherein said micelles comprise sodium dodecyl sulfate (SDS). 4. The method of claim 1, wherein said incorporation in the presence of micelles comprises an additional step of freeze/thaw or sonication. 5. The method of claim 1, wherein said incorporation occurs in the presence of a copper catalyst. 6. The method of claim 1, wherein said incorporation occurs in the presence of copper bromide (CuBr) or copper sulfate (CuSO.sub.4). 7. The method of claim 1, wherein said chemical moiety comprises a functional group selected from the group consisting of: an alkyne, an azide, an alkene, a boronic acid, a silane, an aryl halide, a vinyl halide, and an alkenyl halide. 8. The method of claim 1, wherein said chemical moiety comprises a moiety selected from the group consisting of: a polyethylene glycol (PEG), a polymer, a water soluble polymer, an oligosaccharide, a toxin, a drug, and a polypeptide. 9. The method of claim 1, wherein the polypeptide is selected from the group consisting of: .alpha.-1 antitrypsin, Angiostatin, Antihemolytic factor, an antibody, an antibody fragment, an antibody derivative, a Fab, aFab', aF(ab)2, a Fd, a Fv, a ScFv, a diabody, a tribody, a tetrabody, a dimer, a trimer, a minibody, an angiogenic molecule, an angiostatic molecule, Apolipoprotein, Apoprotein, Atrial natriuretic factor, Atrial natriuretic polypeptide, an Atrial peptide, a C-X-C chemokine, Calcitonin, a CC chemokine, CD40 ligand, C-kit ligand, Chloramphenical acetyltransferase, a Collagen, a Colony stimulating factor, Complement factor 5a, Complement inhibitor, Complement receptor 1, a cytokine, an Epidermal Growth Factor, Erythropoietin, Exfoliating toxins A and B, Factor IX, Factor VII, Factor VIII, Factor X, a Fibroblast Growth Factor, Fibrinogen, Fibronectin, Follitropin, G-CSF, GM-CSF, Glucocerebrosidase, Gonadotropin, growth factor, Hedgehog protein, Hemoglobin, Hepatocyte Growth Factor, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hirudin, Human serum albumin, Human Growth Hormone, Insulin, Insulin-like Growth Factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), interferon alpha (INF-.alpha.), interferon beta (IFN-(.beta.), interferon gamma (IFN-.gamma.), interferon olega (IFN-.OMEGA.), interferon tau (IFN-.tau.), interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 10 (IL-10), interleukin 11 (IL-11), interleukin 12 (IL-12), interleukin 13 (IL-13), interleukin 14 (IL-14), interleukin 15 (IL-15), interleukin 16 (IL-16), interleukin 17 (IL-17), interleukin 18 (IL-18), interleukin 19 (IL-19), interleukin 20 (IL-20), interleukin 21 (IL-21), interleukin 22 (IL-22), interleukin 23 (IL-23), interleukin 24 (IL-24), interleukin 25 (IL-25), interleukin 26 (IL-26), interleukin 27 (IL-27), interleukin 28 (IL-28), interleukin 29 (IL-29), Keratinocyte Growth Factor, Lactoferrin, leukemia inhibitory factor, Luciferase, Neurturin, Neutrophil inhibitory factor, oncostatin M, Osteogenic protein, Parathyroid hormone, platelet-derived erythroid colony stimulating factor (PD-ECSF), platelet derived growth factor (PDGF), peptide hormones, Phenylalanine hydroxylase, Urikase, Pleiotropin, Protein A, Protein G, Pyrogenic exotoxins A, B, and C, Relaxin, Renin, stem cell factor (SCF), Soluble complement receptor I, Soluble inter-cellular adhesion molecule 1 (I-CAM 1), Soluble interleukin receptors, Soluble tumor necrosis factor (TNF) receptor, soluble adhesion molecules, Somatomedin, Somatostatin, Somatotropin, Streptokinase, Superantigen, Staphylococcal enterotoxin, Superoxide dismutase, Toll-like receptors, Toxic shock syndrome toxin, Thymosin .alpha. 1, Tissue plasminogen activator, Tumor necrosis factor .beta., Tumor necrosis factor receptor, Tumor necrosis factor-.alpha., Vascular Endothelial Growth Factor, a virus-like particle, Urokinase; a transcriptional modulator that modulates cell growth, differentiation, or regulation, an expression activator, an inflammatory molecule, a growth factor, a growth factor receptor, an oncogene product, fibroblast growth factor (FGF), insulin growth factor I (IGF-I), insulin growth factor II (IGF-II), TNF, transforming growth factor alpha (TGF-.alpha.), transforming growth factor beta (TGF-.beta.), epidermal growth factor (EGF), keratinocyte growth factor (KGF), c-Kit, CD40L/CD40, very late antigen 4 (VLA-4), vascular cell adhesion molecule 1 (VCAM-1), lymphocyte function-associated antigen 1 (LFA-1), hyalurin/CD44, a signal transduction molecule, a transcriptional activator, a transcriptional suppressor, estrogen, progesterone, testosterone, aldosterone, low density lipoprotein (LDL), corticosterone amidase, amino acid racemase, an acylase, a dehalogenase, a dioxygenase, a diarylpropane peroxidase, an epimerase, epoxide hydrolase, an esterase, an isomerase, a kinase, a glucose isomerase, a glycosidase, a glycosyl transferase, a haloperoxidase, a monooxygenase,a lipase, a lignin peroxidase, nitrile hydratase, nitrilase, protease, a phosphatase, subtilisin, a transaminase, and a nuclease. 10. The method of claim 1, wherein said chemical moiety is incorporated by a single, double or triple carbon-carbon linkage between said chemical moiety and said non-natural amino acid residue. 11. The method of claim 1, wherein said chemical moiety is incorporated by a triazole linkage between said chemical moiety and said non-natural amino acid residue. 12. The method of claim 1, wherein the chemical reaction is Huisgen copper-catalyzed [3+2] cycloaddition. 13. The method of claim 1, wherein said incorporation occurs in the presence of dithiothreitol (DTT). 14. The method of claim 13, wherein said incorporation in the presence of DTT occurs in the presence of oxygen and/or tris(2-carboxyethyl)phosphine (TCEP) and/or copper (Cu(0)). 15. The method of claim 13, wherein said incorporation in the presence of DTT occurs in the presence of oxygen and/or tris(2-carboxyethyl)phosphine (TCEP). 16. The method of claim 13, wherein said incorporation in the presence of DTT occurs in the presence of oxygen. 17. The method of claim 13, wherein said incorporation in the presence of DTT comprises an additional step of freeze/thaw or sonication.

Details for Patent 7,829,659

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2026-05-02
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2026-05-02
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2026-05-02
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2026-05-02
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2026-05-02
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2026-05-02
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2026-05-02